Ovarian cancer future or investigational therapies

Jump to: navigation, search

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer future or investigational therapies

CDC on Ovarian cancer future or investigational therapies

Ovarian cancer future or investigational therapies in the news

Blogs on Ovarian cancer future or investigational therapies

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

Epithelial ovarian cancer patients can have better prognosis and outcome with some under trial Medications that believed to be promising in the future. Examples of the mechanism of action of these promising drugs are, targeting the angiogenesis, targeting (inhibit) DNA repair, targeting cell cycle, targeting signaling pathways, immunotherapeutic medications.

Investigational therapies

References


Linked-in.jpg